SAREPTA THERAPEUTICS, INC. Proceeds from Sale of Restricted Investments
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Sale of Restricted Investments of $10.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-26.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfRestrictedInvestments · last filed 2020-02-26
- SAREPTA THERAPEUTICS, INC. proceeds from sale of restricted investments for the quarter ending 2017-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of restricted investments for the quarter ending 2017-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of restricted investments for the quarter ending 2017-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of restricted investments for the quarter ending 2017-03-31 was $10.70M.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of restricted investments for fiscal 2017 was $10.70M.
- SAREPTA THERAPEUTICS, INC. proceeds from sale of restricted investments for fiscal 2014 was $7.25M.
| Period end | Proceeds from Sale of Restricted Investments 3 month | Proceeds from Sale of Restricted Investments 6 month | Proceeds from Sale of Restricted Investments 9 month | Proceeds from Sale of Restricted Investments 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $0.00 derived: sum of 2 quarters · filed 2020-02-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-26 | $10.70M 10-K · filed 2020-02-26 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $0.00 derived: sum of 2 quarters · filed 2018-10-31 | $10.70M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $10.70M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $10.70M 10-Q · filed 2018-05-03 | |||
| 2014-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $4.00M derived: sum of 2 quarters · filed 2017-02-28 | $7.30M derived: sum of 3 quarters · filed 2017-02-28 | $7.25M 10-K · filed 2017-02-28 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $3.30M derived: sum of 2 quarters · filed 2015-11-05 | $3.25M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $3.30M 10-Q · filed 2014-11-06 | $3.25M 10-Q · filed 2015-08-06 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |